Liraglutide tied to reduced progression of diabetic kidney disease

September 4, 2017

(HealthDay)—For patients with type 2 diabetes and high cardiovascular risk receiving usual care, the addition of liraglutide is associated with lower rates of development and progression of diabetic kidney disease, according to a study published in the Aug. 31 issue of the New England Journal of Medicine.

Johannes F.E. Mann, M.D., from the Friedrich Alexander University of Erlangen in Germany, and colleagues reported the prespecified renal outcomes of a involving with type 2 diabetes receiving usual care who were assigned to liraglutide or placebo. A total of 9,340 patients were randomized and followed for a median of 3.84 years.

The researchers found that the renal outcome (composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease) occurred in fewer participants in the liraglutide versus placebo group (268 of 4,668 versus 337 of 4,672 patients; hazard ratio, 0.78). This result was mainly driven by new onset of persistent macroalbuminuria, which occurred in 161 versus 215 patients in the liraglutide group versus (hazard ratio, 0.74). The rates of renal adverse events, including the rate of acute kidney injury, were similar in the groups.

"This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of than placebo," the authors write.

The study was partially funded by Novo Nordisk, the manufacturer of liraglutide.

Explore further: Liraglutide, sitagliptin have no effect on renal hemodynamics

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Liraglutide, sitagliptin have no effect on renal hemodynamics

September 9, 2016
(HealthDay)—In insulin-naive patients with type 2 diabetes, 12 weeks of treatment with liraglutide or sitagliptin has no effect on renal hemodynamics, according to a study published online Sept. 1 in Diabetes Care.

Valsartan cuts microalbuminuria in impaired glucose tolerance

February 9, 2017
(HealthDay)—For patients with impaired glucose tolerance (IGT), valsartan is associated with reduced incidence of microalbuminuria, according to a study published online Jan. 17 in Diabetes, Obesity and Metabolism.

Thiamine may reduce progression to renal replacement therapy

March 16, 2017
(HealthDay)—For patients in septic shock, thiamine is associated with a lower rate of progression to renal replacement therapy (RRT), according to research published online Feb. 16 in the Annals of the American Thoracic ...

CPAP doesn't alter renal function in coexisting OSA, CVD

August 11, 2017
(HealthDay)—For individuals with coexisting obstructive sleep apnea (OSA) and cardiovascular disease, continuous positive airway pressure (CPAP) does not alter renal function, according to a study published online July ...

Liraglutide increases heart rate in T2DM with stable CAD

October 25, 2016
(HealthDay)—Liraglutide increases heart rate (HR) and reduces heart rate variability (HRV) in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD), according to a study ...

Liraglutide augments weight loss in pre-type 2 diabetes

August 15, 2013
(HealthDay)—For patients at high risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin ...

Recommended for you

Women with pregnancy-related diabetes may be at risk for chronic kidney disease

May 21, 2018
Gestational diabetes may predispose women to early-stage kidney damage, a precursor to chronic kidney disease, according to a study by researchers at the National Institutes of Health and other institutions. The study appears ...

Diabetes researchers find switch for fatty liver disease

May 17, 2018
Duke researchers have identified a key fork in the road for the way the liver deals with carbohydrates, fats and protein. They say it could be a promising new target for combating the pandemics of fatty liver disease and ...

New study of youth with type 1 diabetes connects 'honeymoon period' with lower LDL cholesterol

May 17, 2018
A new study by UMass Medical School physician-scientist Benjamin U. Nwosu, MD, finds that children with type 1 diabetes who experienced a partial clinical remission, or "honeymoon phase," had significantly lower low-density ...

"Living drug factories" may one day replace injections

May 17, 2018
Patients with diabetes generally rely on constant injections of insulin to control their disease. But MIT spinout Sigilon Therapeutics is developing an implantable, insulin-producing device that may one day make injections ...

Boosting the effects of vitamin D to tackle diabetes

May 10, 2018
More than 27 million people in the United States are living with type 2 diabetes, according to the Centers for Disease Control and Prevention. As the population ages and a growing percentage of people become overweight or ...

Very-low-carb diet shows promise in type 1 diabetes

May 7, 2018
Very-low-carbohydrate diets can improve blood sugar control in type 1 diabetes, with low rates of hypoglycemia and other complications, according to an online patient survey. The researchers, led by Belinda Lennerz, MD, PhD, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.